8-K
filed June 29, 2023, 7:59 PM ET
ticker PLX
CIK 0001006281
other material
confidence high
sentiment neutral
materiality 0.15
Protalix adjourns annual meeting to solicit votes for authorized share increase to 185M
Protalix BioTherapeutics, Inc.
- Meeting approved election of 7 directors; votes ranged from 30.1M to 30.7M for, 2.2M to 2.7M withheld.
- Stock plan amendment approved: shares available increased from 8.475M to 12.475M (25.8M for, 6.9M against).
- Advisory vote on say-on-pay frequency favored one year (30.3M votes); board adopts annual frequency.
- Meeting adjourned to July 13, 2023 to solicit more votes for charter amendment increasing authorized shares from 144M to 185M.
- Ratification of PwC as auditor approved with 36.8M for, 2.7M against; broker non-votes existed on other items.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Protalix BioTherapeutics, Inc. shareholders approved Adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan at the 2023-06-28 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-28
Exact text from the filing
(4) Adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan For Against Abstain Broker Non-Votes 25,811,597 6,921,213 108,665 8,872,021
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Protalix BioTherapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers at the 2023-06-28 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-06-28
Exact text from the filing
(3) Approval, on a non-binding advisory basis, the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers One Year Two Years Three Years Abstain Broker Non-Votes 30,261,982 600,162 825,319 1,154,012 8,872,021
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Protalix BioTherapeutics, Inc. shareholders approved Approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2023-06-28 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-28
Exact text from the filing
(2) Approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers For Against Abstain Broker Non-Votes 26,186,630 4,269,510 491,310 8,872,021
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Protalix BioTherapeutics, Inc. shareholders approved Election of Directors at the 2023-06-28 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-28
Exact text from the filing
(1) Election of Directors For Withheld Broker Non-Votes Zeev Bronfeld 30,118,208 2,723,267 8,872,021 Dror Bashan 30,175,739 2,665,736 8,872,021 Amos Bar Shalev 30,118,524 2,722,951 8,872,021 Shmuel “Muli” Ben Zvi, Ph.D. 30,614,690 2,226,785 8,872,021 Pol F. Boudes, M.D. 30,619,760 2,221,715 8,872,021 Gwen A. Melincoff 30,517,556 2,323,919 8,872,021 Aharon Schwartz, Ph.D. 30,659,904 2,181,571 8,872,021
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Protalix BioTherapeutics, Inc. shareholders approved Approval of adjournment of the 2023 Annual Meeting to July 13, 2023 to provide additional time to solicit proxies for a charter amendment at the 2023-06-28 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-06-28
Exact text from the filing
The adjournment was approved by a vote of 39,819,471 shares of Common Stock, with no shares voting against the adjournment or abstaining
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Protalix BioTherapeutics, Inc. shareholders approved Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-28 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-28
Exact text from the filing
(5) Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited For Against Abstain 36,781,844 2,683,094 354,533
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.